Your browser doesn't support javascript.
loading
Oral challenge vs routine care to assess low-risk penicillin allergy in critically ill hospital patients (ORACLE): a pilot safety and feasibility randomised controlled trial.
Rose, Morgan T; Holmes, Natasha E; Eastwood, Glenn M; Vogrin, Sara; James, Fiona; De Luca, Joseph F; Bellomo, Rinaldo; Warrillow, Stephen J; Phung, Michelle; Barnes, Sara L; Murfin, Brendan; Rogers, Ben; Lambros, Belinda; Collis, Brennan; Peel, Trisha N; Slavin, Monica A; Trubiano, Jason A.
Afiliação
  • Rose MT; Department of Infectious Diseases and Immunology, Centre for Antibiotic Allergy and Research, Austin Health, Level 7, Harold Stokes Building, 145 Studley Road, Heidelberg, VIC, 3084, Australia. Morgan.rose2@austin.org.au.
  • Holmes NE; National Centre for Infections in Cancer, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia. Morgan.rose2@austin.org.au.
  • Eastwood GM; Department of Infectious Diseases, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia. Morgan.rose2@austin.org.au.
  • Vogrin S; Department of Infectious Diseases, The Peter Doherty Institute for Infection and Immunity, University of Melbourne, Melbourne, VIC, Australia. Morgan.rose2@austin.org.au.
  • James F; Department of Infectious Diseases and Immunology, Centre for Antibiotic Allergy and Research, Austin Health, Level 7, Harold Stokes Building, 145 Studley Road, Heidelberg, VIC, 3084, Australia.
  • De Luca JF; Department of Infectious Diseases, The Peter Doherty Institute for Infection and Immunity, University of Melbourne, Melbourne, VIC, Australia.
  • Bellomo R; Data Analytics Research and Evaluation Centre, Austin Health/University of Melbourne, Melbourne, VIC, Australia.
  • Warrillow SJ; Department of Intensive Care, Austin Hospital, Heidelberg, VIC, Australia.
  • Phung M; Department of Medicine (St Vincent's Hospital), University of Melbourne, Melbourne, VIC, Australia.
  • Barnes SL; Department of Infectious Diseases and Immunology, Centre for Antibiotic Allergy and Research, Austin Health, Level 7, Harold Stokes Building, 145 Studley Road, Heidelberg, VIC, 3084, Australia.
  • Murfin B; Department of Infectious Diseases and Immunology, Centre for Antibiotic Allergy and Research, Austin Health, Level 7, Harold Stokes Building, 145 Studley Road, Heidelberg, VIC, 3084, Australia.
  • Rogers B; Department of Infectious Diseases, The Peter Doherty Institute for Infection and Immunity, University of Melbourne, Melbourne, VIC, Australia.
  • Lambros B; Department of Intensive Care, Austin Hospital, Heidelberg, VIC, Australia.
  • Collis B; Australian and New Zealand Intensive Care Research Centre, School of Public Health and Preventive Medicine, Monash University, Melbourne, VIC, Australia.
  • Peel TN; Department of Critical Care, The University of Melbourne, Parkville, VIC, Australia.
  • Slavin MA; Department of Intensive Care, Royal Melbourne Hospital, Parkville, VIC, Australia.
  • Trubiano JA; Department of Intensive Care, Austin Hospital, Heidelberg, VIC, Australia.
Intensive Care Med ; 50(6): 913-921, 2024 Jun.
Article em En | MEDLINE | ID: mdl-38739277
ABSTRACT

PURPOSE:

Critically ill patients are vulnerable to penicillin allergy labels that may be incorrect. The validity of skin testing in intensive care units (ICUs) is uncertain. Many penicillin allergy labels are low risk, and validated tools exist to identify those amenable to direct oral challenge. This pilot randomised controlled trial explored the feasibility, safety, and validity of direct enteral challenge for low-risk penicillin allergy labels in critical illness.

METHODS:

Consenting patients with a low-risk penicillin allergy label (PAL) (PEN-FAST risk assessment score < 3) in four ICUs (Melbourne, Australia) were randomised 11 to penicillin (250 mg amoxicillin or implicated penicillin) direct enteral challenge versus routine care (2-h post-randomisation observation for each arm). Repeat challenge was performed post -ICU in the intervention arm. Patients were reviewed at 24 h and 5 days after each challenge/observation.

RESULTS:

We screened 533 patients. 130 (24.4%) were eligible and 80/130 (61.5%) enrolled (age median 64.5 years (interquartile range, IQR 53.5, 74), PEN-FAST median 1 (IQR 0,1)), with 40 (50%) randomised to direct enteral challenge. A positive challenge rate of 2.5% was identified. No antibiotic-associated serious adverse events were identified. 32/40 (80%) received a repeat challenge (zero positive). Post-randomisation, 13 (32%) of the intervention arm and 4 (10%) of the control arm received penicillin (odds ratio, OR 4.33 [1.27, 14.78] p = 0.019).

CONCLUSION:

These findings support the safety, validity, and feasibility of direct enteral challenge for critically ill patients with PEN-FAST assessed low-risk penicillin allergy. The absence of false negative results was confirmed by subsequent negative repeat challenges. A relatively low recruitment to screened ratio suggests that more inclusive eligibility criteria and integration of allergy assessment into routine ICU processes are needed to optimise allergy delabelling in critical illness.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Penicilinas / Estudos de Viabilidade / Estado Terminal / Hipersensibilidade a Drogas / Unidades de Terapia Intensiva Limite: Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Intensive Care Med Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Austrália

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Penicilinas / Estudos de Viabilidade / Estado Terminal / Hipersensibilidade a Drogas / Unidades de Terapia Intensiva Limite: Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Intensive Care Med Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Austrália